Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: insights from the TIGRIS registry (2022)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1016/j.jjcc.2021.10.024
- Subjects: VASOS CORONÁRIOS; INFARTO DO MIOCÁRDIO; FÁRMACOS SINTÉTICOS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Journal of cardiology
- ISSN: 0914-5087
- Volume/Número/Paginação/Ano: v. 79, n. 4, p. 522-529, 2022
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
- Licença: publisher-specific-oa
-
ABNT
RUSSO, Juan J et al. Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: insights from the TIGRIS registry. Journal of cardiology, v. 79, n. 4, p. 522-529, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.jjcc.2021.10.024. Acesso em: 10 jun. 2024. -
APA
Russo, J. J., Yan, A. T., Pocock, S. J., Brieger, D., Owen, R., Sundell, K. A., et al. (2022). Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: insights from the TIGRIS registry. Journal of cardiology, 79( 4), 522-529. doi:10.1016/j.jjcc.2021.10.024 -
NLM
Russo JJ, Yan AT, Pocock SJ, Brieger D, Owen R, Sundell KA, Bagai A, Granger CB, Cohen MG, Nicolau JC. Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: insights from the TIGRIS registry [Internet]. Journal of cardiology. 2022 ; 79( 4): 522-529.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1016/j.jjcc.2021.10.024 -
Vancouver
Russo JJ, Yan AT, Pocock SJ, Brieger D, Owen R, Sundell KA, Bagai A, Granger CB, Cohen MG, Nicolau JC. Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: insights from the TIGRIS registry [Internet]. Journal of cardiology. 2022 ; 79( 4): 522-529.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1016/j.jjcc.2021.10.024 - Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
- Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
Informações sobre o DOI: 10.1016/j.jjcc.2021.10.024 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
